Kane Biotech Schedules First Quarter 2018 Earnings Conference Call and Business Update
Conference call to take place Friday, May 18, 2018 at 8:30am E.T.
WINNIPEG, Manitoba, May 10, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE), (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that it will host a conference call on Friday, May 18, 2018 at 8:30am E.T. to discuss its financial results for the first quarter 2018, in conjunction with the filing of its Quarterly Financial Statements for the first quarter ended March 31, 2018.
Mark Ahrens-Townsend, President and Chief Executive Officer, and Ray Dupuis, Chief Financial Officer of Kane, will host the call and provide an update on recent developments and clinical progress. Management will be answering questions live immediately following the earnings announcement part of the call.
To participate in the call, please dial +1 877-268-9044 (toll-free) in the U.S. and Canada. The conference ID number is 9749257.
|Event:||Kane Biotech Q1 2018 Earnings & Business Update Conference Call|
|Date:||Friday, May 18, 2018|
|U.S. & Canada Dial-in:||877-268-9044 (toll free in Canada and the U.S.)|
A live audio webcast of the conference call will also be available on the investor relations page of Kane’s corporate website at www.kanebiotech.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Kane’s website.
For more information, please visit www.kanebiotech.com or contact:
President & CEO
Kane Biotech Inc.
+1 (204) 477-7592
Vice President - Investor Relations
+1 (646) 653-7035
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
The Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Released May 10, 2018